The safety and immunogenicity of DTaP5-IPV-Hib-HepB fully liquid investigational hexavalent vaccine are comparable with the analogous licensed component vaccines and provide a new combination vaccine option aligned with the recommended US infant immunization schedule, according to a phase-III study of 1,465 participants. Overall, 981 healthy infants were vaccinated in group 1 with the hexavalent vaccine and 484 in group 2 with the analogous licensed component vaccines.
The study found:
• Immune responses in group 1 to all antigens contained in the vaccine 1 month after dose 3 were essentially noninferior to those in group 2.
• Adverse event rates after any dose were similar in both groups.
Citation: Marshall GS, Adams GL, Leonardi ML, et al. Immunogenicity, safety, and tolerability of a hexavalent vaccine in infants. Pediatrics. 2015: 136(2):323-332.
Commentary: Vaccine administration has led to making many diseases, including Haemophilus influenzae type b, polio, and measles quite rare. As we have recently seen with resurgence of measles, continued vigilance and high immunization rates are important in making sure that these diseases remain rare. The development of a hexavalent vaccine is another step in making immunization easier for clinicians to administer and for patients to accept. —Neil Skolnik, MD
This Week's Must Reads
Must Reads in Vaccines
Vaccination for Prevention of Herpes Zoster, Ann Intern Med; ePub 2019 Feb 19; Prosser, et al
ACIP Updates Adult Immunization Schedule, Ann Intern Med; 2019 Feb 5; Kim, Hunter, et al
Influenza Vaccination Safety During Hospitalization, Mayo Clin Proc; ePub 2019 Jan 8; Tartof, et al
Evaluating Vaccination Strategies for Zika Virus, Ann Intern Med; ePub 2018 Apr 3; Durham, et al
2018 Adult ACIP Immunization Schedule Released, Ann Intern Med; 2018 Feb 6; Kim, Riley, et al